Andrew Hirsch bound to BIND as CFO
This article was originally published in Scrip
Executive Summary
BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has appointed Andrew Hirsch CFO. Mr Hirsch previously served as CFO at Avila Therapeutics before its acquisition by Celgene in March 2012. Prior to that, he worked at Biogen Idec for nearly a decade.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.